X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FSD-201 (palmitoylethanolamide) stabilizes mast cells and down-regulates pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of endocannabinoid system of human body.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Immunology Product Name: FSD-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
The acquisition of Lucid represent a positive and exciting step in pursuit of objectives at FSD Pharma owing pipeline of novel, patent-protected drug candidates as Lucid-201, leading edge molecules to target therapies for mental health disorders and neurodegenerative diseases.
Lead Product(s): Lucid-201
Therapeutic Area: Psychiatry/Psychology Product Name: Lucid-201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: FSD Pharma
Deal Size: $8.9 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 21, 2021
Details:
The acquisition of Lucid illustrates FSD Pharma’s vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative diseases in a new way including Lucid's pipeline, Lucid-201.
Lead Product(s): Lucid-201
Therapeutic Area: Psychiatry/Psychology Product Name: Lucid-201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: FSD Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
